Second Annual Conference on
CNS Clinical Trials & Brain Metastases
August 12-13, 2022

This educational event is jointly sponsored by:

SNO
Society for NeuroOncology

ASCO®
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER
The Society for Neuro-Oncology and the American Society of Clinical Oncology gratefully acknowledge the supporters listed below.

**PLATINUM**

- American Brain Tumor Association®
- National Brain Tumor Society
- SONTAG Innovation Fund
- Bristol Myers Squibb™

**GOLD**

- Novocure®

**SILVER**

- Daiichi-Sankyo
- Orbus Therapeutics, Inc.

**BRONZE**

- Illumina®
- Kazia Therapeutics
- Plus Therapeutics
- Monteris Medical
- Seagen
- Varian
Dear Colleagues,

We are delighted to welcome you to the great city of Toronto for the Annual Conference on CNS Clinical Trials & Brain Metastases, co-sponsored by the Society for Neuro-Oncology and the American Society of Clinical Oncology.

This collaborative conference will address the needs of patients with glioblastoma and intracranial malignancy in general, both primary and secondary, and stimulate clinical research in these areas of great unmet clinical need. Research advocating new approaches, out of the box ideas and reforms in the area of neuro-oncology clinical trials will be presented and discussed. The structure will provide a forum that cuts across a large breadth of disciplines and emphasizes aspects of clinical trial design, statistics and interpretation of trial outcomes to develop a better understanding of why numerous glioblastoma and other neuro-oncology clinical trials do not achieve their ultimate objective of prolonging survival of patients and other meaningful clinical measures. In addition, we hope the conference encourages collaboration and cross-fertilization of novel ideas between those invested in the care of patients with primary and secondary malignancies of the CNS.

Toronto is a world class city that is culturally diverse with outstanding attractions, superb restaurants, with warm and friendly locals. The city is easy to navigate, with a network of beautiful pedestrian pathways around the city center. Against this backdrop, we believe the conference will be an outstanding forum for networking and building lasting relationships with like-minded colleagues from around the world.

Thank you again for joining us. We hope you have a productive and enjoyable time in Toronto!
SUPPORTERS

Platinum Level Supporters
American Brain Tumor Association
Bristol-Myers Squibb
National Brain Tumor Society
The Sontag Innovation Fund and Brain Tumor Network

Gold Level Supporter
Novocure Medical Affairs

Silver Level Supporters
Daiichi Sankyo
Orbus Therapeutics

Bronze Level Supporters
Illumina, Inc.
Kazia Therapeutics
Monteris Medical
Plus Therapeutics
Seagen
Varian

MEETING EXHIBITORS

American Brain Tumor Association
Biocept
Bristol-Myers Squibb
Daiichi Sankyo
GT Medical Technologies
Illumina, Inc.
Kazia Therapeutics
Monteris Medical, Inc.
National Brain Tumor Society
Novocure Medical Affairs
Orbus Therapeutics, Inc.
Seagen
The Sontag Innovation Fund and Brain Tumor Network
Varian
Zap Surgical

WIFI is available in the main conference rooms and foyer areas.

Network: Hilton_meeting
Password: SNOASCO22
SCIENTIFIC PROGRAM CO-CHAIRS
Priscilla Brastianos, Massachusetts General Hospital, Harvard Medical School
Mustafa Khasraw, Duke University

PROGRAM COMMITTEE CO-CHAIRS ELECT
Adrienne Boire, Memorial Sloan Kettering Cancer Center
Sarah Goldberg, Yale School of Medicine

PROGRAM COMMITTEE IMMEDIATE PAST CO-CHAIRS
Carey Anders, Duke Cancer Institute
Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto

PROGRAMMING COMMITTEE
Evanthia Galanis, Mayo Clinic
Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center
Sara Hurvitz, University of California, Los Angeles; Jonnson Comprehensive Cancer Center
Rupesh Kotecha, Miami Cancer Institute
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Alireza Mansouri, Penn State Cancer Institute
Minesh Mehta, Miami Cancer Institute
Michael Platten, University Medical Center Mannheim
Mei-Yin C. Polley, University of Chicago
Solmaz Sahebjam, National Cancer Institute, National Institutes of Health
Hussein Tawbi, University of Texas MD Anderson Cancer Center

ABSTRACT REVIEWERS
Christopher Alvarez-Breckenridge
Carey Anders
Adrienne Boire
Priscilla Brastianos
Susan Chang
Caroline Chung
Joseph Costello
Benjamin Ellingson
Peter Fecci
Evanthia Galanis
Sarah Goldberg
Vinai Gondi
Rory Goodwin
Sara Hurvitz
Mustafa Khasraw
Rupesh Kotecha
Emilie Le Rhun
Nancy Lin
Alireza Mansouri
Minesh Mehta
Annette Molinaro
Katherine Peters
Steven Plantadosi
Michael Platten
Mei-Yin Polley
Eudocia Quant Lee
David Reardon
Solmaz Sahebjam
Peter Siegel
Hussein Tawbi
Michael Vogelbaum
Jeffrey Wefel
Michael Weller
Patrick Wen
Frank Winkler
Gelareh Zadeh
Continuing Medical Education Information

Second Annual Conference on CNS Clinical Trials and Brain Metastases
August 12-13, 2022

CONFERENCE OVERVIEW
The Second Annual Conference on CNS Clinical Trials and Brain Metastases — an interactive, interdisciplinary conference on primary and metastatic CNS malignancies — is being held August 12-13, 2022, in Toronto. The goal of this annual Conference is to provide a deeper dive into the area of neuro-oncology clinical trials, to understand how we can make more significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.

LEARNING OBJECTIVES
• Describe how the metastatic brain tumor microenvironment can be leveraged to optimize tumor management.
• Describe multidisciplinary care options for the management of primary and secondary brain tumors.
• Discuss new developments in therapeutic approaches in the treatment of primary and secondary brain tumors.
• Describe recent experimental and clinical advances in the treatment of systemic brain metastases.
• Discuss new therapeutic approaches for malignant diseases of the spinal cord and leptomeninges.
• Identify strategies to integrate supportive and palliative care into the care of patients with primary and metastatic cancers of the CNS.
• Describe basic science’s (translational and correlative) role for discovery of new effective therapies for the management of primary and metastatic brain tumors.
• Discuss current and future approaches for integrating neuroimaging into CNS cancer clinical trials.
• Identify challenges in pediatric investigations that result in the development of clinical trials.
• Identify challenges for the development and approval of novel therapies for CNS cancers.

TARGET AUDIENCE
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates, and Nursing Professionals.

PHYSICIAN ACCREDITATION/CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Society for Neuro-Oncology. Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must attend the meeting in-person and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant within one week of the conference conclusion from “outcomes@globaleducationgroup.com” with the subject line “CME/CE WebSurvey link.”

Deadline to claim CE Credit will be Friday, September 30, 2022 at 11:59pm ET.

This activity is jointly provided by Global Education Group and Society for Neuro-Oncology, and in collaboration with ASCO.

This activity is supported by an educational grant from Medtronic, Inc.
DISCLOSURE OF CONFLICT OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

To view the disclosure list of all individuals in control of content for the program, please click here or visit https://www.soc-neuro-onc.org/WEB/Event_Content/CNS_Clinical_Trials_and_Brain_Metastases/Continuing_Education.aspx

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Society for Neuro-Oncology do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

REFUND/CANCELLATION POLICY

The deadline for cancellations with refund is Monday, August 1, 2022. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Please note that your SNO or ASCO membership must be current if you have chosen to register as a SNO or ASCO member. SNO reserves the right to confirm that you have registered in the correct category.

Payment must be received in full before access to the meeting can be granted.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, caroline@soc-neuro-onc.org.

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

FACULTY

For a list of speakers, please click here or visit https://www.soc-neuro-onc.org/WEB/Event_Content/CNS_Clinical_Trials_and_Brain_Metastases/Continuing_Education.aspx
Friday, August 12, 2022

7:00 - 8:00 AM  Continental Breakfast and Networking  Convention Level Foyer

8:00 - 8:10 AM  Welcome and Program Introduction  Toronto I & II
Tracy Batchelor, Priscilla Brastianos, Mustafa Khasraw

8:10 - 8:45 AM  Keynote
Understanding the Metabolic Dependencies of Brain Metastases
Matt Vander Heiden, Koch Institute for Integrative Cancer Research

8:45 - 10:45 AM  Session 1: Metastasis, Metabolism, Microenvironment  Toronto I & II
Moderators: Adrienne Boire, Paul Kongkham

8:45 - 9:02 AM  Overcoming the Immune-suppressive Microenvironment
Lisa Sevenich, Georg Speyer Haus

9:02 - 9:19 AM  Metabolic Drivers of Brain Metastasis
Michael Pacold, NYU Langone Medical Center

9:19 - 9:36 AM  Fatty Acid Signaling Between Astrocytes and Brain Metastases
Qing Chen, Wistar Institute

9:36 - 9:51 AM  Q&A

9:51 - 9:59 AM  Sting Epigenetic Silencing in Gliomas Can Be Rescued by Methyltransferase Inhibition: Implications for Novel Therapeutic Approaches
Justin Low, Duke University

9:59 - 10:07 AM  Intrathecal Delivery of Dendritic Cell Vaccine Eradicates Tumor Growth and Protects Against Leptomeningeal Disease (LMD) Re-Inoculation in Immunocompetent Her2+ and Triple Negative Breast Cancer (Tnbc) LMD Xenograft Models
Vincent Law, Moffitt Cancer Center and Research Institute

10:07 - 10:15 AM  BSCI-20

10:15 - 10:21 AM  Q&A

10:21 - 10:45 AM  Panel Discussion
Qing Chen, Michael Pacold, Lisa Sevenich, Matt Vander Heiden

10:45 - 11:00 AM  BREAK  Convention Level Foyer

11:00 AM - 1:00 PM  Session 2: Multimodality Approaches to Primary and Secondary Brain Tumors  Toronto I & II
Moderators: Rupesh Kotecha, Minesh Mehta

11:00 - 11:15 AM  Is There a Role for Multi-Modality Therapy in the Modern Era of Melanoma Brain Metastasis?
Zeynep Eroglu, Moffitt Cancer Center

11:15 - 11:30 AM  Designing Trials to Evaluate Combining Radiation and Immunotherapy: Metastasis
Mohammad Khan, Emory University

11:30 - 11:40 AM  Q&A
Friday, August 12, 2022

11:40 - 11:55 AM  Designing Trials to Evaluate Combining Radiation and Immunotherapy: Gliomas
Stephen Bagley, University of Pennsylvania

11:55 - 12:10 PM  Integration of Potent Radiosensitizers with Radiation Therapy for the Treatment of Brain Metastases’
Jann Sarkaria, Mayo Clinic

12:10 - 12:20 PM  Q&A

12:20 - 12:28 PM MMAP-04  Cytotoxic, Tumor-Homing Induced Neural Stem Cells as an Adjuvant to Radiation in the Treatment
of Non-Small Cell Lung Cancer Leptomeningeal Metastases
Alison Mercer-Smith, University of North Carolina -- Chapel Hill

12:28 - 12:36 PM MMAP-05  Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain
Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations: Results From The
Dose-Escalation Cohor
Jonathan Yang, Memorial Sloan Kettering Cancer Center

12:36 - 12:40 PM  Q&A

12:40 - 1:00 PM  Panel Discussion
Stephen Bagley, Zeyn Eroglu, Mohammad Khan, Jann Sarkaria, Susan Chang

1:00 - 2:15 PM  INDEPENDENT LUNCH SESSION: THE TRANSLATION AND UTILITY OF DNA METHYLATION
PROFILING IN CLINICAL PRACTICE - SUPPORTED BY ILLUMINA (Non-CME)  Toronto III

2:15 - 4:00 PM  Session 3: Enhancing Local and Compartmental Therapies  Toronto I & II
Moderator: David Shultz

2:15 - 2:51 PM  Clinical Trials in the Management of Resected Brain Metastases: Can we Improve upon Postop
Single-fractionated Stereotactic Radiosurgery?
- Postop Fractionated Stereotactic Radiosurgery Perspective
  Joshua Palmer, The Ohio State University
- Preop Stereotactic Radiosurgery Perspective
  Debra Nana Yeboa, University of Texas MD Anderson Cancer Center
- Intraop GammaTile Perspective
  Jeffrey Weinberg, University of Texas MD Anderson Cancer Center

2:51 - 2:59 PM LOCL-15  Permanent Carrier-Embedded Cesium-131 Brachytherapy for the Salvage Treatment of Previously
Irradiated, Recurrent Brain Metastases
Nelson S. Moss, Memorial Sloan Kettering Cancer Center

2:59 - 3:07 PM  Discussant
Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center

3:07 - 3:13 PM  Q&A

3:13 - 3:37 PM  Clinical Trials in the Management of Leptomeningeal Dissemination: Can we Improve upon Existing
IT Therapies?
- Proton Cranial Spinal Irradiation Perspective
  Jonathan Yang, Memorial Sloan Kettering Cancer Center
- Intrathecal Immunotherapy Perspective
  Isabella Glitza Oliva, University of Texas MD Anderson Cancer Center
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 3:37 - 3:45 PM | Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases [LM] Phase 1/2a Dose Escalation Trial  
Andrew Brenner, Mays Cancer Center UT Health Science Center, San Antonio |
| 3:45 - 3:53 PM | Discussant                                                                   
Emilie LeRhun, University Hospital Zurich, Switzerland                      |
| 3:53 - 4:00 PM | Q&A                                                                           |
| 4:00 - 4:05 PM | Closing Remarks Day 1                                                        
Priscilla Brastianos, Mustafa Khasraw                                             |
| 4:05 - 4:35 PM | BREAK - Exhibitor Reception                                                      
Convention Level Foyer                                                        |
| 4:35 - 6:10 PM | Town Hall: De-risking and Accelerating Drug Development in CNS Neoplasms (Non-CME) 
Toronto I & II                                                                   
Moderators: Benjamin Ellingson, Victor Levin                                   |
| 4:35 - 4:45 PM | • Problems with CNS Cancer Drug Development: High-risk, Low Reward, High Bar for Return on Investment and the Need for New Drug and Drug Combination Therapies  
Victor Levin, Emeritus, University of Texas MD Anderson Cancer Center       |
| 4:45 - 4:55 PM | • The Venture Capitalist's Perspective on Drug Development in CNS Neoplasms  
Klaus Veitinger, OrbiMed                                                      |
| 4:55 - 5:05 PM | • Preclinical Glioma Models and Strategies to De-risk Later Stage Drug Development  
Howard Fine, Weill Cornell Medicine                                           |
| 5:05 - 5:15 PM | • Preclinical Brain Metastases Models for Drug Development                      
Pat Steeg, National Cancer Institute                                          |
| 5:15 - 5:25 PM | • New Imaging and Modeling Approaches for Quantifying Subclinical Drug Effects in Single Agent and Combination Trials  
Benjamin Ellingson, University of California, Los Angeles; Jonsson Comprehensive Cancer Center |
| 5:25 - 5:35 PM | • De-risking Drug Development and Strategies for Accelerating Drug Development in Primary CNS Neoplasms  
Timothy Cloughesy, University of California, Los Angeles; Jonsson Comprehensive Cancer Center |
| 5:35 - 5:45 PM | • Current Landscape of Drug Development and Strategies for Accelerating Development in Rare and Metastatic Cancer  
Keith Flaherty, Massachusetts General Hospital                                |
| 5:45 - 6:10 PM | Panel Discussion                                                                
Howard Fine, Keith Flaherty, Patricia Steeg, Joohee Sul, Klaus Veitinger, Patrick Wen |
| 6:10 - 6:20 PM | BREAK                                                                        
Convention Level Foyer                                                        |
| 6:20 - 8:20 PM | POSTER AND NETWORKING RECEPTION (Non-CME)                                       
Sheraton Centre Toronto Hotel                                                  |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 - 8:00 AM</td>
<td><strong>Light Continental Breakfast</strong></td>
<td>Convention Level Foyer</td>
</tr>
<tr>
<td>8:00 - 8:05 AM</td>
<td><strong>Welcome and Program Introduction</strong></td>
<td>Toronto I &amp; II</td>
</tr>
<tr>
<td>8:05 - 8:40 AM</td>
<td><strong>Keynote (Non-CME)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>CNS Cancer in the Context of Early Phase Drug Development</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Keith Flaherty, Massachusetts General Hospital</strong></td>
<td></td>
</tr>
<tr>
<td>8:40 - 9:10 AM</td>
<td><strong>Networking Breakfast</strong></td>
<td>Convention Level Foyer</td>
</tr>
<tr>
<td>9:10 - 10:50 AM</td>
<td><strong>Session 4: New Therapies on the Horizon</strong></td>
<td>Toronto I &amp; II</td>
</tr>
<tr>
<td>9:10 - 9:27 AM</td>
<td><strong>Promise of Antibody Drug Conjugates in Breast Cancer Brain Metastases</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Carey Anders, Duke Cancer Institute</strong></td>
<td></td>
</tr>
<tr>
<td>9:27 - 9:44 AM</td>
<td><strong>In Search of Brain Permeable Targeted Therapeutics for Patients with Brain Metastases</strong></td>
<td>Priscilla Brastianos, Massachusetts General Hospital/Harvard Medical School</td>
</tr>
<tr>
<td>9:44 - 10:01 AM</td>
<td><strong>Glioma Systemic Therapy: What is on the Horizon?</strong></td>
<td>Evanthia Galanis, Mayo Clinic</td>
</tr>
<tr>
<td>10:01 - 10:16 AM</td>
<td><strong>Q&amp;A</strong></td>
<td></td>
</tr>
<tr>
<td>10:16 - 10:26 AM</td>
<td><strong>Multi-institutional Randomized Trial Comparing Cancer Stem Cell-targeted Vs Physician-choice Treatments in Patients with Recurrent High-grade Gliomas (NCT03632135)</strong></td>
<td>Soma Sengupta, University of Cincinnati</td>
</tr>
<tr>
<td>10:26 - 10:50 AM</td>
<td><strong>Panel Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:05 AM</td>
<td><strong>BREAK</strong></td>
<td>Convention Level Foyer</td>
</tr>
</tbody>
</table>

### CONCURRENT SESSIONS  11:05 - 12:50 PM

**Concurrent Session 5: Supportive Care in Neuro-Oncology**  
**Toronto III**  
**Moderator: Denise Correa, Yoshie Umemura**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05 - 11:20 AM</td>
<td><strong>Clinical Trials Relevant to Neurocognitive Outcomes and Interventions in Adults with Brain Tumors</strong></td>
<td>Kim Edelstein, Princess Margaret Cancer Centre, University of Toronto</td>
</tr>
<tr>
<td>11:20 - 11:35 AM</td>
<td><strong>Clinical Trials Relevant to Caregiver Support and Quality of Life in Adults with Brain Tumors</strong></td>
<td>Paula Sherwood, University of Pittsburgh, School of Nursing</td>
</tr>
<tr>
<td>11:35 - 11:50 AM</td>
<td><strong>Palliative and Supportive Care Intervention Trials for Patients with Primary and Metastatic Brain Tumors</strong></td>
<td>Deborah Forst, Massachusetts General Hospital</td>
</tr>
</tbody>
</table>
### Concurrent Session 6: Innovations in Spinal Tumors  
**Toronto I & II**

**Moderators:** Rohan Ramakrishna, Rory Goodwin

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:05 - 11:20 AM | Endpoints of Interest in Patients with Spinal Metastasis Disease: What are the Goal Posts We Should Aim for in Clinical Trials?  
*Diva Yerramilli, Memorial Sloan Kettering Cancer Center* |
| 11:20 - 11:35 AM | Spinal LITT: How to Expand Access to Care and Develop an Evidence-based Practice  
*Claudio E. Tatsui, University of Texas MD Anderson Cancer Center* |
| 11:35 - 11:45 AM | Q&A                                                                   |
| 11:45 - 12:00 PM | Percutaneous Interventional Procedures (i.e. RFA / Cryotherapy) in Management of Spine Metastatic Disease -- A Growing Field. Updates for 2022  
*Jason Levy, Interventional Radiology Northside Hospital Atlanta* |
| 12:00 - 12:15 PM | Spine Stereotactic Radiosurgery: Where Do We Go from 24 in 2?  
*Arjun Sahgal, Odette Cancer Centre, Sunnybrook Health Sciences Centre* |
| 12:15 - 12:25 PM | Q&A                                                                   |
| 12:25 - 12:50 PM | Panel Discussion  
*Rupesh Katecha, Jason Levy, Arjun Sahgal, Claudio E. Tatsui, Divya Yerramilli* |
| 12:50 - 1:35 PM | **LUNCH:**  
*Convention Level Foyer* |

### Concurrent Session 7: Current and Future Approaches for Integrating Neuroimaging into CNS Cancer Clinical Trials  
**Toronto I & II**

**Moderators:** Benjamin Ellingson, Alireza Mansouri

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:35 - 1:50 PM | Advanced Imaging Strategies for Early Phase Clinical Trials  
*Javier Villanueva-Meyer, University of California, San Francisco* |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:50 PM</td>
<td>Imaging Strategies for Brain Metastases Clinical Trials</td>
<td>Raymond Huang, Brigham &amp; Women’s Hospital</td>
<td></td>
</tr>
<tr>
<td>2:05 PM</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:09 PM</td>
<td>Combining Clinical Variables and Radiomic Features to Help Distinguish Radiation Necrosis from Tumor in Patients with Melanoma Brain Metastases Treated with Radiosurgery</td>
<td>Benjamin Tran, University of Texas MD Anderson Cancer Center</td>
<td></td>
</tr>
<tr>
<td>2:17 PM</td>
<td>A Phase II Study of Multiparametric MR-guided High Dose Adaptive Radiotherapy with Concurrent Temozolomide in Patients with Newly Diagnosed Glioblastoma</td>
<td>Michelle Kim, University of Michigan</td>
<td></td>
</tr>
<tr>
<td>2:25 PM</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:29 PM</td>
<td>LMD Imaging in Clinical Trials</td>
<td>Emilie Le Rhun, University Hospital Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>2:44 PM</td>
<td>MRI and PET Imaging in PCNSL</td>
<td>Ramon Barajas, Oregon Health &amp; Science University</td>
<td></td>
</tr>
<tr>
<td>2:59 PM</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:03 PM</td>
<td>Panel Discussion</td>
<td>Ramon Barajas, Caroline Chung, Raymond Huang, Emilie LeRhun, Javier Villanueva-Meyer</td>
<td></td>
</tr>
</tbody>
</table>

**Concurrent Session 8: Challenges in Pediatric Investigations** Toronto III

**Moderators:** Michael Taylor, Vijay Ramaswamy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:35 PM</td>
<td>New Vaccines for Childhood Brain Tumors in Ongoing Trials</td>
<td>Duane Mitchell, University of Florida</td>
<td></td>
</tr>
<tr>
<td>1:50 PM</td>
<td>Hypermutant Childhood GBM and How it Can Be Treated with Immunotherapy</td>
<td>Uri Tabori, Hospital for Sick Children</td>
<td></td>
</tr>
<tr>
<td>2:05 PM</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Myc Nuggets: How to Target Your Favorite Transcription Factor</td>
<td>Robert Wechsler-Reya, Sanford Burnham Prebys Medical Discovery Institute</td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Basic Science of CAR T Cells</td>
<td>Laura Donovan, UCL Great Ormond Street Institute of Child Health</td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:55 PM</td>
<td>Intratumoral Delivery of Conditionally Replicative Human Adenovirus 657 Expressing the Immune Co-stimulator CD40L (CRAd657-CD40L) as a Potentially Promising Treatment for Recurrent Pediatric High Grade Glioma</td>
<td>Mason Webb, Mayo Clinic</td>
<td></td>
</tr>
</tbody>
</table>
### Saturday, August 13, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 3:05 - 3:20 PM| Panel Discussion<br>
Laura Donovan, Duane Mitchell, Uri Tabori, Robert Wechsler-Reya       |
| 3:20 - 3:35 PM| BREAK Convention Level Foyer                                          |
| 3:35 - 5:25 PM| **Session 9: How to Get a Therapy to Approval?**<br>
**Toronto I & II**<br>
**Moderators:** Peter Fecci, Evanthia Galanis                             |
| 3:35 - 3:50 PM| What You Need to Proceed to Phase III?<br>
**Michael Weller, Department of Neurology, University Hospital and University of Zurich, Switzerland** |
| 3:50 - 4:10 PM| How to Incorporate Biologic Assessments (Biomarkers, Immune Monitoring, Pd) Into Go/No Go to Take Drugs Further in Clinical Development |
| 3:50 - 4:00 PM| • Brain Mets Perspective<br>
**Michael Davies, University of Texas MD Anderson Cancer Center**       |
| 4:00 - 4:10 PM| • Primary Brain Tumors Perspective<br>
**Howard Fine, Weill Cornell Medicine**                                 |
| 4:10 - 4:25 PM| Methodology and Clinical Trial Design<br>
**Susan Geyer, Mayo Clinic**                                             |
| 4:25 - 4:35 PM| Use of External Control Data for Planning and Analyzing GBM Trials: Ready for Prime Time?<br>
**Mei-Yin Polley, The University of Chicago**                           |
| 4:35 - 4:45 PM| Current State of Clinical Trials for Patients with Melanoma Brain Metastases<br>
**Omar Elghawy, University of Virginia School of Medicine**             |
| 4:45 - 4:50 PM| Q&A                                                                   |
| 4:50 - 5:05 PM| Clinical Trials for Cancer of the CNS, Where to go From Here?<br>
**Mustafa Khasraw, Duke University**                                     |
| 5:05 - 5:25 PM| Panel Discussion<br>
**Howard Fine, Michael Davies, Susan Geyer, Mustafa Khasraw, Michael Weller** |
| 5:25 - 5:30 PM| **Closing Remarks**<br>
**Adrienne Boire, Sarah Goldberg**                                       |
Poster Session Information

FRIDAY, AUGUST 12, 2022
6:20PM - 8:20PM ET
SHERATON CENTRE IN THE DOMINION BALLROOM

Poster Presenters will be responsible for the following:
- Bring a physical (printed) poster
- Measurements of Poster: Not to exceed 44 x 44”
- Remain present at your poster for the duration of the evening
- Setup: Friday, August 12th, 2022, after 12:00pm ET; pushpins will be supplied on site
- Breakdown: Posters must be taken down at the conclusion of the Poster Reception and any remaining posters will be disposed once the reception has concluded.
- Light refreshments and beverages will be served

DIRECTIONS TO THE SHERATON CENTRE

To get to the Sheraton Centre from the Hilton Toronto, it is a quick 3-minute walk.

From the Hilton Toronto:
- Depart the Hilton out of the Richmond entrance and walk to your right toward York Street.
- At York, go to your left.
- Walk one block until Queen Street and go to your right. The Sheraton Centre is on the right side.
- From the lobby, take the elevator or escalator to the second floor of the Sheraton. Signage will direct you to the Dominion Ballroom.
BASIC SCIENCE

BSCI-02 CSF Proteomics as a Minimally-invasive Strategy for Distinguishing Brain Metastases from Other Primary Brain Malignancies
  Alireza Mansouri

BSCI-03 The Role of LonP1 in Driving Enhanced PMT in the ‘Leading Edge’ Niche in Glioblastoma
  Christopher Douglas

BSCI-04 Targeting the PI3K-mTOR pathway to treat UBE2C-driven brain metastases
  Eunice Paisana

BSCI-05 Repurposing Propofol for the Treatment of Brain Metastases
  Donald Penning

BSCI-06 Comprehensive Analysis of the Immunogenomics of Triple Negative Breast Cancer Brain Metastases from LCCC1419
  Amanda Van Swearingen

BSCI-07 Acetyl-Amantadine as a Diagnostic Biomarker in Patients with Glioblastoma
  Anmol Mann

BSCI-08 Neuronal Mimicry Promotes Breast Cancer Leptomeningeal Metastasis From Bone Marrow
  Andrew Whiteley

BSCI-10 Tapping into Gliomas’ Secrets: CSF Proteomics for Biomarker Discovery, Glioma Monitoring, and Therapeutic Response Assessment
  Cecile Riviere-Cazaux

BSCI-11 GB5121 is a Novel, Irreversible, Covalent BTK Inhibitor with High Selectivity and CNS-penetrance for Treatment of CNS Malignancies
  Isharat Yusuf

BSCI-13 Development of Novel Anti-Brain Metastasis Inhibitors
  Agata Kieliszek

BSCI-14 The Role of ICAM1 in Glioblastoma Tumour Associated Macrophages Under Hypoxic Conditions
  Kaviya Devaraja

BSCI-15 Investigating CD8 T Cell Exhaustion States Within the TME and Draining Lymph Node of Primary Brain Tumors and Brain Metastases
  Jessica Waibl Polania

BSCI-17 Topiramate Decreases Radiation-Induced Cytotoxic Edema In Her2+ Brain Metastases via Aquaporin 4 Inhibition
  Maria J Contreras-Zárate

BSCI-18 Estrogen-depletion Decreases Progression of ER+ Brain Metastases by Promoting an Anti-tumoral Local Immune Response
  Diana Cittelly
Posters by Category

BSCI-19  A Lentiviral CRISPR Screen for Epigenetic Modulators of Antigens Targeted by CAR T Cells in Glioblastoma  
T. Jordan Walter

BSCI-21  COX4I1 Expression in Brain Metastases  
Mahak Saad

BSCI-22  Determining the Effect of Novel Small Molecule Drugs Against the Migration of Brain Metastasis Initiating Cells (BMICs)  
Daniel Mobilio

BSCI-23  Aneuploidy Profiling in Glioblastoma Identifies Mechanisms of Disease Progression and Treatment Vulnerabilities  
Anna Jermakowicz

CLINICAL RESEARCH METHODS

CLRM-01  Summary of Virtual Tumor Board Platforms and Implementation in Neuro-Oncology  
Chukwuyem Ekhator

CLRM-02  Single Center Experience of Dopamine Antagonist ONC-201 for Recurrent H3K27M-mutant Glioblastoma in Adults  
Chukwuyem Ekhator

CLRM-03  Incidence of Intracranial Hemorrhage in Glioma Patients with Venous Thromboembolism Converted From LMWH to Apixaban  
Orwa Aboud

CLRM-05  Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis  
Mahalia Dalmage

CLRM-06  Prospective Clinical Study of Conventionally Fractionated Concurrent Chemoradiotherapy and Hypofractionated Concurrent Chemoradiotherapy After the Surgery of High-Grade Gliomas  
Shi Weiyan

CLRM-07  A Multivariate Retrospective Analysis of 159 Patients with High-grade Gliomas: Overall Survival, Progression-free Survival, and Prognostic Factors  
Shiyu Liu

CLRM-09  First-line Tumour Treating Fields (200 kHz) Therapy for Newly-diagnosed Glioblastoma: The Phase 3 TRIDENT Trial (EF-32)  
Wenyin Shi

CLRM-10  METIS (EF-25): A pivotal, Randomized Controlled Study of Tumor Treating Fields in Patients with 1–10 brain Metastases from Non-Small Cell Lung Cancer  
Minesh Mehta

CLRM-12  Stereotactic Radiosurgery (Adjuvant or Neoadjuvant) Compared to Hippocampal Avoidance Whole Brain Radiation Therapy with Simultaneous Integrated Boost for Limited Brain Metastases (SRS-CHART): Phase III Open-label Parallel-group Randomized Controlled Trial  
Jeevi Selvarajan
Posters by Category

CLRM-13  Relevance of Recursive Partitioning Analysis (RPA) Classification in the Current Care of Patients with Brain Metastases (BMETS)
          Guneet Sarai

CLRM-14  Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Live Human Gliomas
          Cecile Riviere-Cazaux

CLRM-15  Trial in Progress: A Phase 1b/2 study of GB5121, a Novel, Highly Selective, Potent, and CNS-penetrant Inhibitor of Bruton’s Tyrosine Kinase (BTKi) for Relapsed/Refractory Primary/Secondary CNS Lymphoma (R/R PCNSL/SCNSL) and Primary Vitreoretinal Lymphoma (PVRL)
          Isharat Yusuf

CLRM-16  Patient-focused Drug Development In Neuro-Oncology: A Pilot Study of Qualitative Patient Interviews Embedded Within a Neurofibromatosis 2 Clinical Trial
          Vanessa Merker

CLRM-18  Screen Failures in Phase III Glioblastoma Clinical Trials
          Katherine Peters

CLRM-19  Using Functional Precision Medicine to Guide Clinical Trial Enrollment in GBM
          Tessa DesRochers

CLRM-20  Identifying Risk Factors and Analyzing Survival Following Pachymeningeal Failure
          Aristotelis Kalyvas

CLRM-21  Risk Factors Associated with the Presence of Brain Metastasis at the Moment of Diagnosis in Lung Cancer Patients: Retrospective Case Series
          Carla M. Martin-Abreu

LOCAL THERAPIES

LOCL-02  Dosimetric and Clinical Analysis of Pseudo-progression vs. Recurrence after Hyper-fractionated Radiotherapy for Brain Metastases Based on Enhanced Magnetic Resonance Imaging
          Siran Yang

LOCL-05  Cerebral Metastatic Lung Carcinoma: Effect of ALK- and EGFR-mutation Status and Surgical Management Upon Clinical Outcome
          Kimberly B. Hoang

LOCL-06  Supervised Machine Learning Identifies Risk Factors Associated with Leptomeningeal Disease After Surgical Resection of Brain Metastases
          Ramin Morshed

LOCL-07  Loco-Regional Infusion of GB-13 (IL13.E13K-PE4E) as a Potentially Promising Treatment for Recurrent High-Grade Glioma
          Soumen Khatua
Posters by Category

LOCL-08  Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1 Trial
Norman LaFrance

LOCL-09  Short-Term Seizure Outcomes in Patients with Treated with Laser Interstitial Thermal Therapy
Emily Lerner

LOCL-10  Evolution of Functional Outcomes After Laser Interstitial Thermal Therapy (LITT) Versus Resection in the Treatment of Lesions In or Near the Primary Motor Cortex
Emily Lerner

LOCL-11  EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) leptomeningeal disease (LMD) in a Large Stereotactic Radiosurgery Patient Cohort: Incidence and Outcome
Reed Mullen

LOCL-12  Outcomes of Stereotactic Radiosurgery for Brain Metastases of Breast Cancer in Relation to Molecular Subtypes
Lærke Wolf Andreasen

LOCL-13  Surgical Resection Plus Stereotactic Radiosurgery (SRS) Versus SRS Alone for Large Posterior Fossa Brain Metastases: Outcomes and Factors Guiding the Decision of Treatment Modality
Ruth Lau-Rodriguez

LOCL-14  Factors Associated with Tract Seeding After Laser Interstitial Thermal Therapy for Intracranial Tumors
Emily Lerner

LOCL-16  Impact of MGMT Promoter Methylation Status on Tumor Dynamics During Weekly Adaptive Radiotherapy for Glioblastoma
John M. Hudson

MULTIMODALITY APPROACHES

MMAP-02  A Population - Based Study on Radiation Therapy for Brain Metastasis from Malignant Melanoma in British Columbia: Evaluating the impact of Immunotherapy and Stereotactic Techniques.
Gaurav Bahl

MMAP-06  Integrated Team-based Brain Metastasis Care Reduces Patient Visits and Shortens Time to Adjuvant Irradiation
Nelson S. Moss

MMAP-07  Impact of Single and Dual Immune Checkpoint Blockade on Risk of Radiation Necrosis Among Patients with Brain Metastases Treated with Stereotactic Radiosurgery
Eugene Vaios

MMAP-08  Chemo-reirradiation (Normofractionated vs. Hypofractionated) with Or without Bevacizumab in Recurrent Adult Diffuse High-grade Glioma (COBRA): Phase III Randomized Controlled Trial with a 2 x 2 Factorial Design
Yamini Baviskar

MMAP-09  Characteristics Correlating with Survival in Patients Treated for Large Brain Metastases
Enrique Gutierrez-Valencia
Posters by Category

**NEUROIMAGING**

**MMAP-10** Adverse Radiation Effect After Stereotactic Radiosurgery and Immunotherapy/Targeted Therapy for Melanoma Brain Metastases  
Christina Phuong

**MMAP-11** Volumetric Study of Brain Metastases in EGFR-Positive NSCLC Treated with Osimertinib With or Without CNS-Directed Radiation Therapy  
Lisa Ni

**NEIM-01** Incidence and Diagnostic Techniques for Leptomeningeal Disease in Patients with Brain Metastasis  
Katie Henry

**NEIM-02** Development of a Deep Learning Model for Discriminating True Progression from Pseudoprogression in Glioblastoma Patients  
Mana Moassefi

**NEIM-03** A Multicenter Phase 3 Trial in Progress: Diagnostic Performance of 18F-Fluciclovine PET for the Detection of Recurrent Brain Metastases After Radiation Therapy (REVELATE)  
Samuel Chao

**NEIM-04** Leveraging Novel Neuroimaging Techniques to Link Brain Metastases and Local Gene Expression.  
Aaron Loh

**NEIM-05** Feasibility of Navigated Transcranial Magnetic Stimulation (nTMS) Based Diffusion Tensor Imaging (DTI) Tractography of Motor Pathways in Patients Undergoing Stereotactic Radiosurgery: A Cross-sectional Dosimetric and Patient Outcomes Analysis  
Julianna Bronk

**NEIM-07** Differential Diagnosis of Tumor Recurrence and Radiation Necrosis After Stereotactic Radiotherapy for Brain Metastases with 320-row ADCT Perfusion Image and T1/T2 Match: Radiological and Pathological Analysis  
Koichi Mitsuya

**SUPPORTIVE CARE**

**SPCR-01** RapidPlan Hippocampal Sparing Whole Brain Model Version 2 - How Far Can We Reduce the Dose?  
Hefei Liu

**INNOVATIONS IN SPINAL TUMORS**

**SPIN-01** Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation/Vertebral Augmentation for Spine Metastasis: Trial in Progress  
Rupesh Kotecha

**SPIN-02** Leveraging an MRI-guided Linear Accelerator Platform for Post-Operative Stereotactic Body Radiation Therapy (SBRT) of Spinal Metastases  
Ariel E. Marciscano
Posters by Category

**SYSTEMIC THERAPEUTICS**

SYST-03  Incidence and Survival of Patients with Intracranial Metastatic Disease and ERBB2-positive Gastrointestinal Cancers: A Retrospective Cohort Study  
Madison Sherman

SYST-04  Preliminary Report of a Clinical Trial Evaluating the Safety and Efficiency of Neoadjuvant Camrelizumab and Apatinib In Patients With Recurrent High-Grade Gliomas: A Prospective, phase II, Single-arm Study  
Zhongping Chen

SYST-05  Optimizing HER2-targeted Therapies (TT) for Breast Cancer (BC) Leptomeningeal Metastases (LM): a Systematic Review and Meta-analysis  
Matthew Dankner

SYST-06  Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC Enrolled in VISION  
Natasha Leighl

SYST-07  Window-of-opportunity Study of ONC201 in Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) and Thalamic Glioma  
Yazmin Odia

SYST-08  Survival Analysis of Metastatic Melanoma Patients with Brain Metastasis Using Surveillance, Epidemiology, and End Results (SEER)  
Angel Baroz

SYST-09  Impact of End-stage Renal Disease and Concomitant Dialysis on the Efficacy of Immunotherapy in Brain Metastases Patients: A Propensity-matched Survival Analysis  
Angel Baroz

SYST-10  CSNO2012001 Study: A Phase III Trial on Adjuvant Temozolomide Chemotherapy with or without Interferon-alpha in Newly Diagnosed High-grade Gliomas  
Chengcheng Guo

SYST-11  Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM  
Chengcheng Guo

SYST-12  D2C7 CAR: A Novel CAR T Cell That Simultaneously Targets Wildtype EGFR and Its Mutant isoform EGFRvIII for Treatment of Glioma and Brain Metastases  
Daniel Wilkinson

SYST-13  Phase II Study of The Combination of Liposomal Irinotecan and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) with Brain Metastases (BM)  
Jian Campian

SYST-14  Clinical Efficacy of ONC201 in Recurrent H3 K27M-mutant Diffuse Midline Glioma (DMG) Patients  
Joshua E. Allen

SYST-15  Targeting Axonal Guidance with Anti-ROBO1 CAR T Cells: A New Therapeutic Strategy for Malignant Brain Cancer  
Benjamin Brakel

SYST-16  Propensity-matched Survival Analysis of Second and Third Generation Tyrosine Kinase Inhibitors in the Treatment of Brain Metastases from Lung Cancer Primary  
Debarati Bhanja
Join Us Next Year in
San Francisco
August 10-12, 2023
Hyatt Regency Embarcadero

3rd Annual Conference jointly sponsored by the Society for Neuro-Oncology and the American Society of Clinical Oncology